Therapy of psoriasis in childhood and adolescence - a German expert consensus.
Standard
Therapy of psoriasis in childhood and adolescence - a German expert consensus. / Sticherling, Michael; Augustin, Matthias; Boehncke, Wolf-Henning; Christophers, Enno; Domm, Silja; Gollnick, Harald; Reich, Kristian; Mrowietz, Ulrich.
in: J DTSCH DERMATOL GES, Jahrgang 9, Nr. 10, 10, 2011, S. 815-823.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Therapy of psoriasis in childhood and adolescence - a German expert consensus.
AU - Sticherling, Michael
AU - Augustin, Matthias
AU - Boehncke, Wolf-Henning
AU - Christophers, Enno
AU - Domm, Silja
AU - Gollnick, Harald
AU - Reich, Kristian
AU - Mrowietz, Ulrich
PY - 2011
Y1 - 2011
N2 - Psoriasis of childhood shows an annual prevalence of 0.71 % and accordingly has to be regarded as a frequent chronic inflammatory skin disorder of this age. The impact on the quality of life as well as development of the afflicted children and their parents is evident. On the other side, therapy is demanding with regard to the specific juvenile metabolism, physical development and skin penetration of topical drugs. Long-term treatment at an early age has to be critically judged regarding the chronicity of the disease. Topical corticosteroids, alternatively dithranol may be used first-line, followed by vitamin D derivatives. A combination with UV-light, preferably UV-B, has to be decided on an individual basis. Systemic treatment may be initiated in recalcitrant disease with methotrexate and cyclosporine where long-term experience is available from juvenile rheumatology and transplantation medicine. Alternatively fumaric acid esters or retinoids are available. Rehabilitation procedures will help the children and their parents to cope with the disease and its treatment. The different treatment options are presented here as a German expert consensus, as clinical studies are hardly available and only a few therapeutics are licensed for this age. In any case the therapy has to be individually planned and decided together with the patients and their parents to gain maximal safety, comfort and success.
AB - Psoriasis of childhood shows an annual prevalence of 0.71 % and accordingly has to be regarded as a frequent chronic inflammatory skin disorder of this age. The impact on the quality of life as well as development of the afflicted children and their parents is evident. On the other side, therapy is demanding with regard to the specific juvenile metabolism, physical development and skin penetration of topical drugs. Long-term treatment at an early age has to be critically judged regarding the chronicity of the disease. Topical corticosteroids, alternatively dithranol may be used first-line, followed by vitamin D derivatives. A combination with UV-light, preferably UV-B, has to be decided on an individual basis. Systemic treatment may be initiated in recalcitrant disease with methotrexate and cyclosporine where long-term experience is available from juvenile rheumatology and transplantation medicine. Alternatively fumaric acid esters or retinoids are available. Rehabilitation procedures will help the children and their parents to cope with the disease and its treatment. The different treatment options are presented here as a German expert consensus, as clinical studies are hardly available and only a few therapeutics are licensed for this age. In any case the therapy has to be individually planned and decided together with the patients and their parents to gain maximal safety, comfort and success.
KW - Germany
KW - Humans
KW - Adolescent
KW - Child
KW - Cross-Sectional Studies
KW - Administration, Oral
KW - Administration, Topical
KW - Adrenal Cortex Hormones/administration & dosage/adverse effects/pharmacokinetics
KW - Anthralin/administration & dosage/adverse effects/pharmacokinetics
KW - Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Dermatologic Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Psoriasis/diagnosis/drug therapy/epidemiology
KW - Skin Absorption/drug effects
KW - Skin Care/methods
KW - Urea/administration & dosage/adverse effects/pharmacokinetics
KW - Germany
KW - Humans
KW - Adolescent
KW - Child
KW - Cross-Sectional Studies
KW - Administration, Oral
KW - Administration, Topical
KW - Adrenal Cortex Hormones/administration & dosage/adverse effects/pharmacokinetics
KW - Anthralin/administration & dosage/adverse effects/pharmacokinetics
KW - Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Dermatologic Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Psoriasis/diagnosis/drug therapy/epidemiology
KW - Skin Absorption/drug effects
KW - Skin Care/methods
KW - Urea/administration & dosage/adverse effects/pharmacokinetics
M3 - SCORING: Journal article
VL - 9
SP - 815
EP - 823
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 10
M1 - 10
ER -
